Optimizing lornoxicam-loaded poly(lactic-co-glycolic acid) and (polyethylene glycol) nanoparticles for transdermal delivery: ex vivo/in vivo inflammation evaluation.
Nanomedicine (Lond)
; 19(16): 1471-1485, 2024 07 02.
Article
en En
| MEDLINE
| ID: mdl-38953843
ABSTRACT
Aim:
This study focused on developing a topical gel incorporating lornoxicam-loaded poly(lactic-co-glycolic acid) and polyethylene glycol (PLGA-PEG) blend nanoparticles to mitigate gastrointestinal (GIT) side effects and enhance therapeutic efficacy. Materials &methods:
Synthesized nanoparticles were subjected to in vitro characterization, ex vivo permeation studies, and acute oral toxicity analysis post-incorporation into the gel using a S/O/W double emulsion solvent. Results &conclusion:
The nanoparticles displayed a smooth, spherical morphology (170-321 nm) with increased entrapment efficiency (96.2%). LOX exhibited a permeation rate of 70-94% from the nanoparticle-infused gel, demonstrating favorable biocompatibility at the cellular level. The formulated gel, enriched with nanoparticles, holds promising prospects for drug-delivery systems and promising improved therapeutic outcomes for LOX.
[Box see text].
Palabras clave
Texto completo:
1
Base de datos:
MEDLINE
Asunto principal:
Polietilenglicoles
/
Administración Cutánea
/
Piroxicam
/
Nanopartículas
/
Copolímero de Ácido Poliláctico-Ácido Poliglicólico
Límite:
Animals
/
Humans
/
Male
Idioma:
En
Revista:
Nanomedicine (Lond)
Año:
2024
Tipo del documento:
Article
País de afiliación:
Pakistán